Clinical Highlights

Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds

Dermatologic Surgery

• Author: Gary Monheit, M.D.
• Published on March 24, 2020

DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)

Journal of the American Academy of Dermatology

• Author: Vince Bertucci, M.D. et al
• Published on December 2, 2019

Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles

Dermatologic Surgery

• Author: Berthold Rzany, M.D. et al
• Published on October 10, 2019

DaxibotulinumtoxinA in the treatment of glabellar lines. Results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)

Plastic and Reconstructive Surgery

• Author: Jean Carruthers M.D. et al
• Published on October 10, 2019

Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate‐to‐severe nasolabial folds: A 64‐week, prospective, multicenter, controlled, randomized, double‐blind and within‐subject study

Journal of Cosmetic Dermatology

• Author: Joely Kaufman-Janette MD et al.
• Published on August 24, 2019

Announcing Sakura 3 Results

Disclaimer: DaxibotulinumtoxinA for Injection is currently an investigational product and not approved by FDA. Anticipated approval in 2020.

More than 73.5% subjects in Sakura 1 and 2 achieved a two-grade improvement in glabellar lines as assessed by with the patient and the investigator at week 4 after treatment¹